MyoKardia, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Other
VRXValeant Pharmaceuticals International, Inc. -0.70%28.2014.1%$165.93m
AMRNAmarin Corp. Plc -2.87%19.641.7%$157.21m
AXSMAxsome Therapeutics, Inc. 0.18%85.351.9%$90.76m
BHCBausch Health Cos., Inc. -0.63%28.220.0%$84.06m
GWPHGW Pharmaceuticals Plc -2.06%112.166.2%$72.11m
PRGOPerrigo Co. Plc -0.10%58.706.8%$63.68m
JAZZJazz Pharmaceuticals Plc -1.11%144.132.3%$63.24m
SAVACassava Sciences, Inc. 3.14%7.400.0%$62.71m
ICPTIntercept Pharmaceuticals, Inc. -3.19%93.5716.9%$59.55m
SAGESAGE Therapeutics, Inc. -1.13%67.258.6%$57.95m
HZNPHorizon Therapeutics Plc -0.78%35.786.6%$55.97m
MNKMallinckrodt Plc -4.64%4.9320.9%$41.66m
ICLRICON plc -1.99%171.474.2%$38.77m
CTLTCatalent, Inc. 0.29%61.762.4%$38.07m
UTHRUnited Therapeutics Corp. 0.90%90.1314.3%$35.11m

Company Profile

MyoKardia, Inc. operates as a biopharmaceutical company. It engages in the discovery, development, and commercialization of targeted therapies for the treatment of cardiovascular diseases. The firm focuses on the treatment of heritable cardiomyopathies, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. It offers MYK-46, an orally-administered small molecule designed to reduce excessive cardiac muscle contractility to hypertrophic cardiomyopathy. The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in San Francisco, CA.